Page 39 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of $3.10 per share. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,903,226 additional … – Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of $3.10 per share. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,903,226 additional shares of its common stock. All of the s

New yorkUnited statesAnthony marcianoExchange commissionEquity syndicate departmentSeelos therapeutics incHead of corporate communicationsGuggenheim securitiesSeelos therapeuticsBenchmark companyAcute suicidal ideationMajor depressive disorderPost traumatic stress disorderLooking statementsPrivate securities litigation reform actSeelo annual report